Copyright © Inderes 2011 - present. All rights reserved.
Regulatory press release

Interim report January - June 2024

Flerie
Download the release

April – June 2024
· Net asset value was SEK 4,380 million (3,511) and net asset value per share was SEK 56.10 (57.80), adjusted net asset value per share was SEK 57.41 (57.80)
· Change in net asset value per share was -0.3 per cent (-1.1), adjusted change in net asset value per share was 2.1 per cent
· Total fair value of shares in portfolio companies was SEK 3,058 million (3,041)
· Change in fair value of shares in portfolio companies was SEK 172 million (-58), equivalent to 6.2 per cent (-2.0).
· Net profit/loss amounted to SEK 103 million (-38)
· Profit per share before and after dilution amounted to SEK 1.59 (-0.63)
· Net sales was SEK 0.1 million (-)

January – June 2024
· Change in net asset value per share was -4.4 per cent (5.4), adjusted change in net asset value per share was -2.2 per cent
· Change in fair value of shares in portfolio companies was SEK 19 million (2), equivalent to 0.7 per cent (0.1).
· Net profit/loss amounted to SEK -47 million (-38)
· Profit per share before and after dilution amounted to SEK -0.75 (-0.07)
· The expense ratio amounted to 1.3 per cent (1.2)
· Cash and cash equivalents amounted to SEK 882 million (355)
· Net sales was SEK 0.1 million (-)

Significant events during the quarter
· In May, an agreement was entered into between Flerie Invest and Flerie AB (former InDex Pharmaceuticals) to carry out a reverse merger. The transaction was closed in June and brought SEK 223 million of cash to Flerie Invest. In June a directed share issue was carried out which brought the Company circa SEK 607 million before transaction costs.
· Investments in the Product Development segment was SEK 135 million.
· At an EGM in June, it was decided to introduce a share redemptionprogram. The program enables an annual redemption of up to five percent of the share capital with Q2 2025 as the first redemption opportunity.
· On June 27, Flerie's shares began trading on Nasdaq Stockholm.
· XNK Therapeutics was declared bankrupt on 8 April. The full value of the company was written down during the first quarter, equivalent to SEK 59 million.

Shareholders, financial analysts and media are kindly invited to a webcast in English, including presentation of the quarterly results and a Q&A, today the 17th of July 2024 at 14:00 CET.

Please register via the link below. Note that it can take several minutes to receive the confirmation email with the teams link.
Microsoft Virtual Events Powered by Teams

The presentation will be available after the webcast at Flerie.com.

For more information:

Ted Fjällman, CEO
Email: ir@flerie.com

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

This information is information that Flerie AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-17 08:00 CEST.

Attachments
Flerie AB Interim Report January June 2024